Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marat Fudim, Kishan Parikh, Arun Ganesh, Jeroen Molinger, Neil Ray, Aubrie Coburn, Brian J Coyne, Ashley G Swavely, Jennifer Andrews, James Matthew Gray, Vishal N Rao, G Michael Felker, Salvador Borges-Neto, Adrian F Hernandez, Manesh R Patel
No abstract text is available yet for this article.
March 16, 2023: European Journal of Heart Failure
#2
JOURNAL ARTICLE
Suleman Aktaa, Chris P Gale, Margarita Brida, George Giannakoulas, Gabor Kovacs, Yochai Adir, Raymond L Benza, Michael Böhm, Andrew Coats, Michele D'Alto, Pilar Escribano-Subias, Pisana Ferrari, Nazzareno Galie, J Simon R Gibbs, Wendy Gin-Sing, Marius M Hoeper, Marc Humbert, Irene M Lang, Bradley A Maron, Gergely Meszaros, Anton Vonk Noordegraaf, Laura C Price, Joanna Pepke-Zaba, Göran Rådegran, Abilio Reis, Olivier Sitbon, Adam Torbicki, Silvia Ulrich, Stephan Rosenkranz, Marion Delcroix
AIMS: To develop a suite of quality indicators (QIs) for the evaluation of the care and outcomes for adults with pulmonary arterial hypertension (PAH). METHODS AND RESULTS: We followed the ESC methodology for the development of QIs. This included the 1) identification of key domains of care for the management of PAH, 2) proposal of candidate QIs following systematic review of the literature, and 3) selection of a set of QIs using a modified-Delphi method. The process was undertaken in parallel with the writing of the 2022 European Society of Cardiology (ESC) / European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension and involved Task Force chairs, experts in PAH, Heart Failure Association (HFA) members and patient representatives...
March 16, 2023: European Journal of Heart Failure
#3
EDITORIAL
Clément Delmas, Laurent Bonello, François Roubille
No abstract text is available yet for this article.
March 16, 2023: European Journal of Heart Failure
#4
REVIEW
Faiez Zannad, Jacqueline Alikhaani, Sadegh Alikhaani, Javed Butler, Jason Gordon, Klaus Jensen, Rani Khatib, Lorenzo Mantovani, Robin Martinez, Wanda F Moore, Masahiro Murakami, Lothar Roessig, Norman Stockbridge, Harriette G C Van Spall, Clyde Yancy, John A Spertus
There are many consequences of heart failure (HF), including symptoms, impaired health-related quality of life (HRQoL), and physical and social limitations (functional status). These have a substantial impact on patients' lives, yet are not routinely captured in clinical trials. Patient-reported outcomes (PROs) can quantify patients' experiences of their disease and its treatment. Steps can be taken to improve the use of PROs in HF trials, in regulatory and payer decisions, and in patient care. Importantly, PRO measures (PROMs) must be developed with involvement of patients, family members, and caregivers from diverse demographic groups and communities...
March 16, 2023: European Journal of Heart Failure
#5
JOURNAL ARTICLE
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.
Stephen J H Dobbin, Li Shen, Mark C Petrie, Milton Packer, Scott D Solomon, John J V McMurray, Ninian N Lang, Pardeep S Jhund
AIMS: Heart failure (HF) therapy trials usually exclude cancer patients. We examined the association between cancer history and outcomes in trial participants with HF and reduced (HFrEF) or preserved ejection fraction (HFpEF). METHODS AND RESULTS: We combined PARADIGM-HF and ATMOSPHERE, which enrolled HFrEF patients (n = 15 415) and we pooled HFpEF patients (ejection fraction ≥45%) enrolled in PARAGON-HF and CHARM-Preserved (n = 7363)...
March 15, 2023: European Journal of Heart Failure
#6
JOURNAL ARTICLE
Alberto Aimo, Daniela Tomasoni, Aldostefano Porcari, Giuseppe Vergaro, Vincenzo Castiglione, Claudio Passino, Marianna Adamo, Maria Giulia Bellicini, Carlo Mario Lombardi, Matilde Nardi, Gloria Palamara, Guerino Giuseppe Varrà, Riccardo Saro, Valentina Allegro, Marco Merlo, Gianfranco Sinagra, Marco Metra, Michele Emdin, Claudio Rapezzi
AIMS: Cardiac amyloidosis (CA) is due to a deposition of amyloid fibrils in the heart causing an increase in wall thickness. A left ventricular (LV) wall thickness ≥12 mm plus at least one red flag should raise the suspicion of CA. As normal values of LV wall thickness are lower in women, the adoption or the same cut-off values for men and women could lead to underdiagnosis or delayed diagnosis in women. We investigated the relationship between LV wall thickness and the severity of cardiac involvement in women and men with transthyretin (ATTR) CA...
March 15, 2023: European Journal of Heart Failure
#7
LETTER
Arjun K Pandey, Nitish K Dhingra, Avinash Pandey, Pankaj Puar, Shamon Ahmed, Raj Verma, C David Mazer, Javed Butler, Mitesh Badiwala, Terrence M Yau, Bobby Yanagawa, Deepak L Bhatt, Subodh Verma
No abstract text is available yet for this article.
March 15, 2023: European Journal of Heart Failure
#8
JOURNAL ARTICLE
Yuki Saito, Masaru Obokata, Tomonari Harada, Kazuki Kagami, Hidemi Sorimachi, Naoki Yuasa, Toshimitsu Kato, Naoki Wada, Yasuo Okumura, Hideki Ishii
AIMS: Pulmonary hypertension (PH) and pulmonary vascular remodelling are common in patients with heart failure with preserved ejection fraction (HFpEF). Many patients with HFpEF demonstrate an abnormal pulmonary haemodynamic response to exercise that is not identifiable at rest. This can be estimated non-invasively by the mean pulmonary artery pressure-cardiac output relationship (mPAP/CO slope). We sought to characterize the pathophysiology of disproportionate exercise-induced PH in relation to CO (DEi-PH) and its prognostic impact in patients with HFpEF...
March 13, 2023: European Journal of Heart Failure
#9
JOURNAL ARTICLE
Matteo Pagnesi, Marianna Adamo, Jozine M Ter Maaten, Iris E Beldhuis, Gad Cotter, Beth A Davison, G Michael Felker, Gerasimos Filippatos, Barry H Greenberg, Peter S Pang, Piotr Ponikowski, Iziah E Sama, Thomas Severin, Claudio Gimpelewicz, Adriaan A Voors, John R Teerlink, Marco Metra
AIMS: The impact of mitral regurgitation (MR) in patients hospitalized for acute heart failure (AHF) is not well established. We assessed the role of MR in patients enrolled in the Relaxin in Acute Heart Failure 2 (RELAX-AHF-2) trial. METHODS AND RESULTS: Patients enrolled in RELAX-AHF-2 with available data regarding MR status were included in this analysis. Baseline characteristics, in-hospital data, and clinical outcomes through 180-day follow-up were evaluated...
March 13, 2023: European Journal of Heart Failure
#10
JOURNAL ARTICLE
Giacomo Tini, Paolo Milani, Mattia Zampieri, Angelo Giuseppe Caponetti, Francesca Fabris, Andrea Foli, Alessia Argirò, Carlotta Mazzoni, Christian Gagliardi, Simone Longhi, Giulia Saturi, Giuseppe Vergaro, Alberto Aimo, Domitilla Russo, Guerino Giuseppe Varrà, Matteo Serenelli, Gioele Fabbri, Laura De Michieli, Giuseppe Palmiero, Giuseppe Ciliberti, Samuela Carigi, Eugenio Sessarego, Giulia Elena Mandoli, Giulia Ricci Lucchi, Valeria Rella, Enrico Monti, Elisa Gardini, Michela Bartolotti, Lia Crotti, Elisa Merli, Roberta Mussinelli, Pier Filippo Vianello, Matteo Cameli, Francesca Marzo, Federico Guerra, Giuseppe Limongelli, Alberto Cipriani, Stefano Perlini, Laura Obici, Federico Perfetto, Camillo Autore, Italo Porto, Claudio Rapezzi, Gianfranco Sinagra, Marco Merlo, Beatrice Musumeci, Michele Emdin, Elena Biagini, Francesco Cappelli, Giovanni Palladini, Marco Canepa
BACKGROUND: Epidemiology of wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) remains poorly defined. A better characterization of pathways leading to ATTRwt-CA diagnosis is of key importance, and potentially informative of disease course and prognosis. OBJECTIVES: To describe characteristics of contemporary pathways leading to ATTRwt-CA diagnosis, and their potential association with survival. METHODS: This was a retrospective study of patients diagnosed with ATTRwt-CA at 17 Italian referral centres for CA...
March 12, 2023: European Journal of Heart Failure
#11
REVIEW
Alberto Giannoni, Chiara Borrelli, Francesco Gentile, Paolo Sciarrone, Jens Spießhöfer, Massimo Piepoli, George B Richerson, John S Floras, Andrew Js Coats, Shahrokh Javaheri, Michele Emdin, Claudio Passino
The importance of chemoreflex function for cardiovascular health is increasingly recognized in clinical practice. The physiological function of the chemoreflex is to constantly adjust ventilation and circulatory control to match respiratory gases to metabolism. This is achieved in a highly integrated fashion with the baroreflex and the ergoreflex. The functionality of chemoreceptors is altered in cardiovascular diseases, causing unstable ventilation and apnoeas and promoting sympathovagal imbalance, and it is associated with arrhythmias and fatal cardiorespiratory events...
March 12, 2023: European Journal of Heart Failure
#12
JOURNAL ARTICLE
Stephen William Sheridan, Friedrich Wetterling, Jeffrey Moore Testani, Barry A Borlaug, Marat Fudim, Kevin Damman, Alastair Gray, Peter Gaines, Martin Poloczek, Stephen Madden, James Tucker, Teresa Buxo, Robert Gaul, Louise Corcoran, Fiachra Sweeney, Daniel Burkhoff
AIMS: The management of congestion is one of the key treatment targets in heart failure. Assessing congestion is, however, difficult. The purpose of this study was to investigate the safety and dynamic response of a novel, passive, inferior vena cava (IVC) sensor in a chronic ovine model. METHODS AND RESULTS: A total of 20 sheep divided into three groups were studied in acute and chronic in vivo settings. Group I and Group II included 14 sheep in total with 12 sheep receiving the sensor and two sheep receiving a control device (IVC filter)...
March 9, 2023: European Journal of Heart Failure
#13
JOURNAL ARTICLE
Sebastian Ludwig, Daniel Kalbacher, Walid Ben Ali, Jessica Weimann, Matti Adam, Alison Duncan, John G Webb, Stephan Windecker, Mathias Orban, Cristina Giannini, Augustin Coisne, Nicole Karam, Andrea Scotti, Lars Sondergaard, Marianna Adamo, David W M Muller, Christian Butter, Paolo Denti, Bruno Melica, Damiano Regazzoli, Andrea Garatti, Tobias Schmidt, Martin Andreas, Gry Dahle, Maurizio Taramasso, Georg Nickenig, Nicolas Dumonteil, Thomas Walther, Michele Flagiello, Joerg Kempfert, Neil Fam, Hendrik Ruge, Tanja K Rudolph, Moritz C Wyler von Ballmoos, Marco Metra, Simon Redwood, Juan F Granada, Gilbert H L Tang, Azeem Latib, Philipp Lurz, Ralph Stephan von Bardeleben, Thomas Modine, Jörg Hausleiter, Lenard Conradi
AIMS: This study aimed to compare outcomes after transcatheter mitral valve replacement (TMVR) and mitral valve transcatheter edge-to-edge repair (M-TEER) for the treatment of secondary mitral regurgitation (SMR). METHODS AND RESULTS: The CHOICE-MI registry included 262 patients with SMR treated with TMVR between 2014 and 2022. The EuroSMR registry included 1065 patients with SMR treated with M-TEER between 2014 and 2019. Propensity score (PS) matching was performed for 12 demographic, clinical and echocardiographic parameters...
March 8, 2023: European Journal of Heart Failure
#14
JOURNAL ARTICLE
Vanessa Blumer, Lauren K Truby, Shelley Zieroth
No abstract text is available yet for this article.
February 28, 2023: European Journal of Heart Failure
#15
JOURNAL ARTICLE
Milton Packer
No abstract text is available yet for this article.
February 28, 2023: European Journal of Heart Failure
#16
JOURNAL ARTICLE
Finn Gustafsson, Kevin Damman, Sanem Nalbantgil, Linda W Van Laake, Laurens F Tops, Thomas Thum, Stamatis Adamopoulos, Michael Bonios, Andrew Js Coats, Maria G Crespo-Leiro, Mandeep R Mehra, Gerasimos Filippatos, Loreena Hill, Marco Metra, Ewa Jankowska, Nicolaas de Jonge, David Kaye, Marco Masetti, John Parissis, Davor Milicic, Petar Seferovic, Giuseppe Rosano, Tuvia Ben Gal
This clinical consensus statement reviews the use of inotropic support in patients with advanced heart failure. The current guidelines only support use of inotropes in the setting of acute decompensated heart failure with evidence of organ malperfusion or shock. However, inotropic support may be reasonable in other patients with advanced heart failure without acute severe decompensation. The clinical evidence supporting use of inotropes in these situations is reviewed. Particularly, patients with persistent congestion, systemic hypoperfusion, or advanced heart failure with need for palliation, and specific situations relevant to implantation of left ventricular assist devices or heart transplantation are discussed...
February 27, 2023: European Journal of Heart Failure
#17
JOURNAL ARTICLE
Emma K Gard, Anna L Beale, Fernando Telles, Frank E Silvestry, Thomas Hanff, Scott L Hummel, Sheldon E Litwin, Mark C Petrie, Sanjiv J Shah, Barry A Borlaug, Dan Burkhoff, Jan Komtebedde, David M Kaye, Shane Nanayakkara
AIMS: Elevated left atrial (LA) pressure is a pathophysiologic hallmark of heart failure with preserved ejection fraction (HFpEF). Chronically elevated LA pressure leads to LA enlargement, which may impair LA function and increase pulmonary pressures. We sought to evaluate the relationship between LA volume and pulmonary arterial haemodynamics in patients with HFpEF. METHODS AND RESULTS: Data from 85 patients (aged 69 ± 8 years) who underwent exercise right heart catheterisation and echocardiography were retrospectively analysed...
February 27, 2023: European Journal of Heart Failure
#18
EDITORIAL
Ovidiu Chioncel, Laura Antohi, Alexandre Mebazaa
No abstract text is available yet for this article.
February 23, 2023: European Journal of Heart Failure
#19
JOURNAL ARTICLE
Kent Y Feng, Andrew P Ambrosy, Zhipeng Zhou, Ditian Li, Jeremy Kong, Jonathan G Zaroff, Jacob M Mishell, Ivy A Ku, Andrea Scotti, Augustin Coisne, Björn Redfors, Michael J Mack, William T Abraham, JoAnn Lindenfeld, Gregg W Stone
AIMS: Low serum albumin levels are associated with poor prognosis in numerous chronic disease states but the relationship between albumin and outcomes in patients with heart failure (HF) and secondary mitral regurgitation (SMR) has not been described. METHODS AND RESULTS: The randomized COAPT trial evaluated the safety and effectiveness of transcatheter edge-to-edge repair (TEER) with the MitraClip plus guideline-directed medical therapy (GDMT) versus GDMT alone in patients with symptomatic HF and moderate-to-severe or severe SMR...
February 23, 2023: European Journal of Heart Failure
#20
JOURNAL ARTICLE
Fraser J Graham, Pierpaolo Pellicori, Paul R Kalra, Ian Ford, Dario Bruzzese, John G F Cleland
AIMS: For patients with heart failure (HF) and iron deficiency (ID), randomized trials suggest that intravenous (IV) iron reduces hospitalizations for heart failure (HHF), but uncertainty exists about the effects in subgroups and the impact on mortality. We conducted a meta-analysis of randomized trials investigating the effect of IV iron on clinical outcomes in patients with HF. METHODS AND RESULTS: We identified randomized trials published between 1 January 2000 and 5 November 2022 investigating the effect of IV iron versus standard care/placebo in patients with HF and ID in any clinical setting, regardless of HF phenotype...
February 23, 2023: European Journal of Heart Failure
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
